# Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101

> **NCT06545162** · PHASE1 · COMPLETED · sponsor: **Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.** · enrollment: 72 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **BIOLOGICAL:** CPX101 or placebo 80mg single dose
- **BIOLOGICAL:** CPX101 or placebo 120mg single dose
- **BIOLOGICAL:** CPX101 or placebo 160mg single dose
- **BIOLOGICAL:** CPX101 or placebo 80mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 120mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 160mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 320mg Q2W

## Key facts

- **NCT ID:** NCT06545162
- **Lead sponsor:** Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-04
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545162, "Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06545162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*